TISCH

1. Smith CB, Phillips T, Smith TJ. Using the New ASCO Clinical Practice Guideline for Palliative Care Concurrent With Oncology Care Using the TEAM Approach. Am Soc Clin Oncol Educ Book. 2017;37:714-723. doi: 10.14694/EDBK_175474. PubMed PMID: 28561696. 2. Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. J Gastroenterol. 2017 May 29. doi: 10.1007/s00535-017-1352-z. [Epub ahead of print] PubMed PMID: 28555325. 3. Germain D. Toward the identification and the targeting of key players of the mitochondrial unfolded protein response (UPR(mt)) in cancer. J Bioenerg Biomembr. 2017 May 29. doi: 10.1007/s10863-017-9716-x. [Epub ahead of print] PubMed PMID: 28555290. 4. Molotkov A, Mazot P, Brewer JR, Cinalli RM, Soriano P. Distinct Requirements for FGFR1 and FGFR2 in Primitive Endoderm Development and Exit from Pluripotency. Dev Cell. 2017 May 23. pii: S1534-5807(17)30386-6. doi: 10.1016/j.devcel.2017.05.004. [Epub ahead of print] PubMed PMID: 28552557.